Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed Amendment No. 5 to Schedule 13G with the SEC on November 16, 2026, disclosing their beneficial ownership of common shares in Structure Therapeutics Inc. as of September 30, 2026.
Key Highlights
- Three reporting persons: Deep Track Capital, LP (Delaware), Deep Track Biotechnology Master Fund, Ltd. (Cayman Islands), and David Kroin (United States) filed jointly.
- Aggregate beneficial ownership: Each reporting person is listed as beneficially owning 15,000,000 common shares of Structure Therapeutics Inc.
- Percent of class: The 15,000,000 shares represent 7.18% of the class, calculated based on 208,862,772 common shares outstanding as of July 31, 2026, according to the filing.
- Share composition: The 15,000,000 ordinary shares consist of 5,000,000 American Depositary Shares, each of which represents, and at the holder's option is convertible into, three ordinary shares, according to the filing.
- Voting and dispositive power: Each reporting person reports 0 sole voting power and 0 sole dispositive power, with 15,000,000 shared voting power and 15,000,000 shared dispositive power.
- Control person: The filing states that "Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person."
- Event date: The date of the event requiring this filing is September 30, 2026.
Deep Track Capital's Disclosed Position in Structure Therapeutics as of September 30, 2026
According to the Schedule 13G/A filed on November 16, 2026, Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 15,000,000 common shares of Structure Therapeutics Inc. (CUSIP 86366E106). The filing is Amendment No. 5 to their Schedule 13G, with the triggering event dated September 30, 2026. Structure Therapeutics Inc. is headquartered at 601 Gateway Blvd., Suite 900, South San Francisco, CA 94080, according to the filing.
The filing states that the 15,000,000 ordinary shares are held in the form of 5,000,000 American Depositary Shares, each representing three ordinary shares and convertible into ordinary shares at the holder's option. The percent-of-class figure of 7.18% is derived from 208,862,772 common shares outstanding as of July 31, 2026, as reported in the issuer's 10-Q filed with the SEC on August 6, 2026, according to the filing. All voting and dispositive power is reported as shared among the reporting persons, with no sole power reported by any party.
David Kroin signed the filing in three capacities: as Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP; as Director of Deep Track Biotechnology Master Fund, Ltd.; and in his individual capacity. The filing certifies, as required, that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," per the standard Schedule 13G certification language.
What Was Disclosed
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed Amendment No. 5 to Schedule 13G disclosing shared beneficial ownership of 15,000,000 Structure Therapeutics Inc. common shares, equal to 7.18% of the class, as of September 30, 2026.




Please wait processing your request...